Good Results of the Respiratory Syncytial Virus (RSV) Immunization Campaign
The immunization campaign against the Respiratory Syncytial Virus (RSV), the main cause of bronchiolitis, has achieved an 89% reduction in admissions for this disease in the Pediatrics department of the Figueres Hospital. This first mass neonatal immunization campaign with Nirsevimad to tackle RSV started five months ago, on October 2, 2023, and has shown very positive uptake especially in the first trimester.
Coverage and Involvement of the Pediatric Team
During the period from October to December 2023, the coverage of the campaign was 92%, and 71% in the first two months of 2024. The head of the Pediatric Service of the Empordà Health Foundation (FSE), Pili Villalobos , highlights the full involvement of the pediatric team at the Figueres Hospital in these high immunization results, both medical and nursing and nursing assistants.
Evaluation and Analyzed Data
The technicians of the Glòria Compte Research Institute have evaluated the care records of babies born in Alt Empordà between October 2023 and February 2024, analyzing socio-demographic data, health, nationality, acceptance of immunization and RSV income. In addition, they have also examined admissions associated with RSV infection in children under two years of age at Figueres Hospital in different periods.
Acceptance of Immunization and Differences between Nationalities
According to the director of Research, Innovation and Development of the FSE, Pere Plaja, it has been observed that there are no significant differences between the nationalities of the mother in relation to the acceptance of immunization, although a minor has been detected acceptance in a specific indigenous ethnic group. This coincides with the data presented by the Department of Health of the Generalitat de Catalunya.
